TABLE 6.
Incidence of rare irAEs in hematological malignancies.
| Rare Toxicities | ||||||
| Author | Condition | Phase | Regimen | Symptom | Incidence | |
| all grade | grade ≥ 3 | |||||
| Cardiotoxicity | ||||||
| Mateos et al. (2019b) | RR MM | 3 | pembro + pom + dex | myocarditis | 1% | 1% |
| Usmani et al. (2019) | ND MM | 3 | pembro + lena + dex | myocarditis | 1% | 1% |
| Younes et al. (2017) | ND FL | 1b/2 | atezo + obi + benda | myocarditis | 3% | 3% |
| Neurotoxicity | ||||||
| Diefenbach et al. (2020) | RR cHL | 1/2 | ipili + BV | peripheral sensory neuropathy | 69% | 4% |
| nivo + BV | 53% | 0% | ||||
| ipili + nivo + BV | 36% | 0% | ||||
| Cohen et al. (2021) | RR MM | 2/3 | cetreli + dara | autoimmune encephalitis | 11% | 0% |
| D’Souza et al. (2019) | ND MM | 2 | pembro + lena | neuropathy | 7% | 0% |
| Zeidan et al. (2018) | RR MDS | 1b | ipili | Bell´s palsy | 3% | 0% |
| Other | ||||||
| Liu et al. (2021) | RR cHL | 2 | camre + decitabine | myalgia | 10% | 0% |
| Shi et al. (2021) | RR PTCL | 2 | geptanolimab | arthralgia | 2% | 0% |
| AI hemolytic anemia | 1% | 1% | ||||
| Diefenbach et al. (2020) | RR cHL | 1/2 | ipili + nivo + BV | arthritis | 5% | 5% |
| Song et al. (2020) | RR cHL | 2 | tislelizumab | osteoarthritis | 1% | NA |
| kidney injury | 1% | 1% | ||||
| Mei et al. (2020) | RR PMBL | 2 | camre + GVD | myalgia | 4% | 0% |
| Khodadoust et al. (2016) | RR MF, RR SS | 2 | pembro | arthralgia + arthritis | 13% | 4% |
| corneal ulcer | 4% | 4% | ||||
| Zinzani et al. (2019) | RR PMBL | 1/2 | nivo + BV | kidney injury | 7% | 3% |
| Barta et al. (2019) | RR T-NHL | 2 | pembro | vasculitis | 6% | 6% |
| HLH | 6% | 6% | ||||
| Ansell et al. (2019) | RR DLBCL | 2 | nivo | nephritis + renal dysfunction | NA | 4% |
| Armand et al. (2019) | RR PMBL | 1b | pembro | myositis | 5% | 5% |
| Davids et al. (2016) | RR hematol. malign. | 1/1b | ipili | ITP | 4% | 0% |
| Bashey et al. (2009) | cancer post HSCT | 1 | ipili | polyarthritis | 3% | 3% |
| D’Souza et al. (2019) | ND MM | 2 | pembro + lena | arthralgia | 3% | 0% |
| glomerulonephritis | 3% | 3% | ||||
| Davids et al. (2020) | RR hematol. malign. | 1 | nivo | arthralgia | 11% | 4% |
| Daver et al. (2019) | RR AML | 2 | nivo + azacitidine | HLH | 1% | 1% |
| Zeidan et al. (2018) | RR MDS | 1b | ipili | myositis | 3% | 0% |
RR, relapsed/refractory; ND, newly diagnosed; cHL, classical Hodgkin lymphoma; FL, follicular lymphoma; PTCL, peripheral T cell lymphoma; NHL- non-Hodgkin lymphoma; MM, multiple myeloma; PMBL, primary mediastinal large B cell lymphoma; DLBCL, diffuse large B cell lymphoma; MF, mycosis fungoides; SS, Sézary syndrome; AML, acute myeloid leukemia; MDS, myelodysplastic syndrome; HSCT, (allogeneic) hematopoietic stem cell transplantation; atezo, atezolizumab; ipili, ipilimumab; nivo, nivolumab; obi, obinutuzumab; benda, bendamustin; BV, brentuximab vedotin; GVD, gemcitabine + vinorelbine + doxorubicin; pembro, pembrolizumab; pom, pomalidomide; lena, lenalidomide; cetreli, cetrelimab; dara, daratumumab; dex, dexamethasone; ida, idarubucin; camre, camrelizumab; AI, autoimmune; HLH, hemophagocytic lymphohistiocytosis; ITP, immune thrombocytopenia.